Drug Trial Radar · NCT07413133
A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Feb 11, 2026
Primary completion
Jun 19, 2026
Study completion Jun 19, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
Conditions
- Healthy Volunteer
Interventions
ABBV-8736Drug
Intravenous Injection
ABBV-8736Drug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to At Least 3 Months
- Maximum Observed Serum Concentration (Cmax) of ABBV-8736Time frame: Up to At Least 3 Months
- Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736Time frame: Up to At Least 3 Months
- Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736Time frame: Up to At Least 3 Months
- AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736Time frame: Up to At Least 3 Months
- Terminal Phase Elimination Rate Constant (β) of ABBV-8736Time frame: Up to At Least 3 Months
- Terminal Elimination Half-Life (t1/2) of ABBV-8736Time frame: Up to At Least 3 Months
- Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736Time frame: Up to At Least 3 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CenExel ACT- Anaheim Clinical Trials /ID# 280481
Anaheim, California
Acpru /Id# 280382
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.